Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study-Reference-Cited by-同舟云学术

Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study

Published:2020-12-19 Issue:1 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Ruggiero Angelo¹^ORCID,Fabbrocini Gabriella¹,Cinelli Eleonora¹^ORCID,Megna Matteo¹^ORCID

Affiliation:

1. Section of Dermatology, Department of Clinical Medicine and Surgery University of Naples Federico II Napoli Italy

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14673

Reference20 articles.

1. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice

2. Psoriatic Arthritis

3. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”

4. Guselkumab: First Global Approval

5. IL-23 inhibitors for moderate-to-severe psoriasis

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence of advanced systemic pharmacological treatment of moderate‐to‐severe psoriasis among bio‐naïve patients—A retrospective register‐based cohort study in Finland and Sweden;Journal of the European Academy of Dermatology and Venereology;2024-08-02

2. Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study;Journal of the European Academy of Dermatology and Venereology;2024-06-26

3. Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study;Journal of Clinical Medicine;2024-05-03

4. Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study;Journal of Clinical Medicine;2024-04-26

5. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study);Journal of Dermatological Treatment;2024-02-27